{
    "clinical_study": {
        "@rank": "137872", 
        "arm_group": {
            "arm_group_label": "Topical Testosterone Solution", 
            "arm_group_type": "Experimental", 
            "description": "Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate if testosterone solution can raise testosterone hormone levels into\n      the normal range after treatment for up to 9 Weeks, in those participants with a documented\n      history of subtherapeutic levels (total testosterone <300 nanograms per deciliter [ng/dL])\n      when previously treated with a topical testosterone gel."
        }, 
        "brief_title": "The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hypogonadism", 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to read, understand, and provide signed informed consent before starting trial\n             activities related to this study (including discontinuing testosterone replacement\n             therapy prior to Screening)\n\n          -  Male participants with a diagnosis of hypogonadism and documented biochemical failure\n             (total testosterone <300 ng/dL) when treated with the highest dose of a topical\n             testosterone gel tolerated by the participant. Documentation of biochemical failure\n             includes: the name and dose of the topical testosterone gel, a lab report showing a\n             total testosterone level <300 ng/dL while on therapy, or a written chart report\n             stating that there was a clear lack of efficacy, including the participant's serum\n             total testosterone level at the time of failure\n\n          -  Screening serum total testosterone level of <300 ng/dL (based on the average of 2\n             morning blood samples taken at least 30 minutes apart) at Screening\n\n          -  Prostate Specific Antigen (PSA) <4 nanogram per milliliter (ng/ml) at Screening\n\n          -  If the participant is receiving testosterone replacement therapy and is willing to\n             discontinue testosterone replacement therapy to enter the study, their screening\n             total testosterone level cannot be checked until at least 14 days after discontinuing\n             topical therapies, or after at least 28 days for participants using short-acting\n             intramuscular (IM) therapies\n\n        Exclusion Criteria:\n\n          -  Any previous treatment with testosterone topical solution (LY900011)\n\n          -  Known or suspected carcinoma (or history of carcinoma) of the prostate or suspicious\n             nodules on digital rectal exam at Screening\n\n          -  Known or suspected breast cancer or history of breast cancer\n\n          -  Severe sleep apnea (untreated or unsuccessfully treated) in the opinion of the study\n             investigator\n\n          -  Use of long-acting IM testosterone undecanoate in the 6-month period prior to\n             Screening\n\n          -  History of the use of an implanted testosterone pellets (Testopel)\n\n          -  International Prostate Symptom Score (IPSS) total score >19 at Screening\n\n          -  Hematocrit \u226550% at Screening. For sites located at elevations \u22654500 feet,\n             participants will be excluded with hematocrit >54% according to investigator\n             discretion. Any participant with a hematocrit >54% at later study visits will be\n             withdrawn from the study\n\n          -  Significant history of allergy and/or sensitivity to the drug products or excipients,\n             including any history of sensitivity to testosterone and/or sunscreens\n\n          -  Dermatologic condition in underarm area that might interfere with testosterone\n             absorption (for example, eczema) or that could be exacerbated by topical testosterone\n             replacement therapy\n\n          -  History of luteinizing hormone-releasing hormone (LHRH) antagonist or agonist\n             treatment in the 6 months prior to Screening\n\n          -  Exhibit any evidence of congestive heart failure (New York Heart Association [NYHA]\n             Class 2 or above) within 6 months prior to Screening\n\n          -  Exhibit evidence of severe renal impairment (creatinine clearance <30 milliliter per\n             minute [mL/min] as determined by the Cockcroft-Gault formula) at Screening\n\n          -  Exhibit a history of severe liver disease or clinical evidence of hepatic impairment\n             at Screening\n\n          -  Any condition that would interfere with the participant's ability to provide informed\n             consent, or comply with study instructions, or would place the participant at\n             increased risk, or might confound the interpretation of the study results\n\n          -  Are investigator site personnel directly affiliated with this study and/or their\n             immediate families. Immediate family is defined as a spouse, parent, child, or\n             sibling, whether biological or legally adopted\n\n          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical\n             trial involving an investigational product or non-approved use of a drug or device\n             (other than the investigational product used in this study), or are concurrently\n             enrolled in any other type of medical research judged not to be scientifically or\n             medically compatible with this study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893281", 
            "org_study_id": "14980", 
            "secondary_id": "I5E-US-TSBC"
        }, 
        "intervention": {
            "arm_group_label": "Topical Testosterone Solution", 
            "description": "Administered topically to axillae.", 
            "intervention_name": "Topical Testosterone Solution", 
            "intervention_type": "Drug", 
            "other_name": [
                "LY900011", 
                "Axiron", 
                "Testosterone Solution 2%"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Encinitas", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92024"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parker", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80134"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30501"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coeur D' Alene", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83814"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anderson", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46011"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeffersonville", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47130"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Billings", 
                        "country": "United States", 
                        "state": "Montana", 
                        "zip": "59101"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elkhorn", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68022"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marlton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08053"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garden City", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11530"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poughkeepsie", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12601"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cary", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27518"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Concord", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28025"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salisbury", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28144"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marshall", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75670"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Round Rock", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78681"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78228"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of Participants Achieving Normal Serum Testosterone Levels", 
            "safety_issue": "No", 
            "time_frame": "Baseline through Study Completion (Up to 9 Weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Serum Testosterone Levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Study Completion (Up to 9 Weeks)"
            }, 
            {
                "measure": "Proportion of Participants in each Category of the Patient Global Impression - Improvement Scales (PGI-I)", 
                "safety_issue": "No", 
                "time_frame": "Study Day 15, 22, 36, 43, 57, and 64"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}